<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02336594</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA3170-110</org_study_id>
    <nct_id>NCT02336594</nct_id>
  </id_info>
  <brief_title>RDEA3170 Bioavailability Study</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability of Two RDEA3170 Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, open-label, 4-way crossover pharmacokinetic (PK) and
      pharmacodynamic (PD) study in healthy adult male subjects designed to assess the relative
      bioavailability of RDEA3170 2.5 mg tablets administered as a 10 mg dose (2.5 mg × 4 tablets)
      and of a single RDEA3170 10 mg tablet. This study will also assess the effect of a low-fat
      and high-fat meal on the PK and PD of RDEA3170 10 mg tablets.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Days 1 and 5 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>Cmax of RDEA3170 in fasted condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Occurrence of Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Days 1 and 5 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>Tmax of RDEA3170 following various treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Quantifiable Last Sampling Timepoint (AUC Last)</measure>
    <time_frame>Days 1 and 5 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>AUC last of RDEA3170 in fasted condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From 0 to Infinity (AUC∞)</measure>
    <time_frame>Days 1 and 5 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>AUC∞ of RDEA3170 the fasted condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Terminal Half-life (t1/2)</measure>
    <time_frame>Days 1 and 5 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>t1/2 of RDEA3170 following various treatments.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Effect of High Fat Meal on the PK of RDEA3170 Tablets</measure>
    <time_frame>Days 1 to 13 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>Cmax of RDEA3170 in high-fat fed state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC Last: Effect of High Fat Meal on the PK of RDEA3170 Tablets</measure>
    <time_frame>Days 1 to 13 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>AUC last of RDEA3170 in high-fat fed state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞: Effect of High Fat Meal on the PK of RDEA3170 Tablets</measure>
    <time_frame>Days 1 to 13 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>AUC∞ of RDEA3170 in high-fat fed state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Effect of Low Fat Meal on the PK of RDEA3170 Tablets</measure>
    <time_frame>Days 1 to 9 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>Cmax of RDEA3170 in low-fat fed state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC Last: Effect of Low Fat Meal on the PK of RDEA3170 Tablets</measure>
    <time_frame>Days 1 to 9 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>AUC last of RDEA3170 in low-fat fed state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC∞: Effect of Low Fat Meal on the PK of RDEA3170 Tablets</measure>
    <time_frame>Days 1 to 9 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
    <description>AUC∞ of RDEA3170 in low-fat fed state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single Dose Pharmacodynamics (PD) Profile of RDEA3170 From Serum and Urine</measure>
    <time_frame>Day -1: -24, -23, -22, -21, -20, -18, -16, -14, and -12 hours predose. Days 1, 5, 9, and 13: predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose.</time_frame>
    <description>PD profiles of uric acid from serum and urine. PD parameters were evaluated to assess whether any potential differences in PK for the 2 different tablets resulted in differences in uric acid excretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>7 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Sequence ABCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 mg x 4 tablets qd (once daily) fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BACD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence ABDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 x 4 mg tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence BADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170 10 mg</intervention_name>
    <arm_group_label>Sequence ABCD</arm_group_label>
    <arm_group_label>Sequence BACD</arm_group_label>
    <arm_group_label>Sequence ABDC</arm_group_label>
    <arm_group_label>Sequence BADC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA3170 2.5 mg</intervention_name>
    <arm_group_label>Sequence ABCD</arm_group_label>
    <arm_group_label>Sequence BACD</arm_group_label>
    <arm_group_label>Sequence ABDC</arm_group_label>
    <arm_group_label>Sequence BADC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is able to understand the study procedures and the risks involved and is
             willing to provide written informed consent before the first study-related activity

          -  Subject has a body weight ≥ 50 kg (110 lbs.) and a body mass index ≥ 18 and ≤ 40 kg/m2

          -  Subject has a Screening serum urate level ≤ 7 mg/dL

          -  Subject is free of any clinically significant disease or medical condition, per the
             Investigator's judgment

        Exclusion Criteria:

          -  Subject has a history or suspicion of kidney stones

          -  Subject has undergone major surgery within 3 months prior to Screening

          -  Subject donated blood or experienced significant blood loss (&gt; 450 mL) within 12 weeks
             prior to Day 1 or gave a plasma donation within 4 weeks prior to Day 1

          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture

          -  Subject has a Screening serum creatinine value above the upper limit of normal during
             Screening or at Day -2 (Admission)

          -  Subject cannot swallow multiple tablets

          -  Subject is a heavy caffeine drinker

          -  Subject is unwilling to comply with the dietary restrictions of the study

          -  Subject is unable or unwilling to comply with the study requirements or has a
             situation or condition that, in the opinion of the Investigator, may interfere with
             participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Hall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <results_first_submitted>May 15, 2017</results_first_submitted>
  <results_first_submitted_qc>October 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 13, 2017</results_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>15 subjects were randomized</recruitment_details>
      <pre_assignment_details>Fifteen subjects were randomized to 1 of 4 treatment sequences (ABCD, BACD, ABDC, BADC) in a 1:1:1:1 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence ABCD</title>
          <description>Day 1 (Treatment A): 10 mg dose of RDEA3170, administered as 4 × 2.5 mg ER tablets, in the fasted state; Day 5 (Treatment B): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fasted state; Day 9 (Treatment C): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fed state (low-fat, high-calorie meal); Day 13 (Treatment D): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fed state (high-fat, high-calorie meal).</description>
        </group>
        <group group_id="P2">
          <title>Sequence BACD</title>
          <description>Day 1 (Treatment B): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fasted state; Day 5 (Treatment A): 10 mg dose of RDEA3170, administered as 4 × 2.5 mg ER tablets, in the fasted state; Day 9 (Treatment C): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fed state (low-fat, high-calorie meal); Day 13 (Treatment D): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fed state (high-fat, high-calorie meal).</description>
        </group>
        <group group_id="P3">
          <title>Sequence ABDC</title>
          <description>Day 1 (Treatment A): 10 mg dose of RDEA3170, administered as 4 × 2.5 mg ER tablets, in the fasted state; Day 5 (Treatment B): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fasted state; Day 9 (Treatment D): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fed state (high-fat, high-calorie meal); Day 13 (Treatment C): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fed state (low-fat, high-calorie meal).</description>
        </group>
        <group group_id="P4">
          <title>Sequence BADC</title>
          <description>Day 1 (Treatment B): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fasted state; Day 5 (Treatment A): 10 mg dose of RDEA3170, administered as 4 × 2.5 mg ER tablets, in the fasted state; Day 9 (Treatment D): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fed state (high-fat, high-calorie meal); Day 13 (Treatment C): 10 mg dose of RDEA3170, administered as a single 10 mg ER tablet, in the fed state (low-fat, high-calorie meal).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence ABCD</title>
          <description>2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat.</description>
        </group>
        <group group_id="B2">
          <title>Sequence BACD</title>
          <description>10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat</description>
        </group>
        <group group_id="B3">
          <title>Sequence ABDC</title>
          <description>2.5 x 4 mg tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat</description>
        </group>
        <group group_id="B4">
          <title>Sequence BADC</title>
          <description>10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="9.8"/>
                    <measurement group_id="B2" value="39" spread="9.7"/>
                    <measurement group_id="B3" value="40" spread="12.3"/>
                    <measurement group_id="B4" value="42" spread="16.0"/>
                    <measurement group_id="B5" value="42" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <description>Cmax of RDEA3170 in fasted condition.</description>
        <time_frame>Days 1 and 5 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>10 mg dose of RDEA3170, administered as 4 × 2.5 mg tablets, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <description>Cmax of RDEA3170 in fasted condition.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="11.7" upper_limit="16.8"/>
                    <measurement group_id="O2" value="14.9" lower_limit="11.9" upper_limit="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the Pharmacokinetics (PK), Pharmacodynamics (PD), and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio (%)</param_type>
            <param_value>107</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.2</ci_lower_limit>
            <ci_upper_limit>120</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Occurrence of Maximum Observed Concentration (Tmax)</title>
        <description>Tmax of RDEA3170 following various treatments.</description>
        <time_frame>Days 1 and 5 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>10 mg dose of RDEA3170, administered as 4 × 2.5 mg tablets, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (low-fat, high calorie meal).</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (high-fat, high calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Occurrence of Maximum Observed Concentration (Tmax)</title>
          <description>Tmax of RDEA3170 following various treatments.</description>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="1.50" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to the Quantifiable Last Sampling Timepoint (AUC Last)</title>
        <description>AUC last of RDEA3170 in fasted condition.</description>
        <time_frame>Days 1 and 5 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>10 mg dose of RDEA3170, administered as 4 × 2.5 mg tablets, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to the Quantifiable Last Sampling Timepoint (AUC Last)</title>
          <description>AUC last of RDEA3170 in fasted condition.</description>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" lower_limit="96.8" upper_limit="146"/>
                    <measurement group_id="O2" value="114" lower_limit="85.7" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio (%)</param_type>
            <param_value>97.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.6</ci_lower_limit>
            <ci_upper_limit>111</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From 0 to Infinity (AUC∞)</title>
        <description>AUC∞ of RDEA3170 the fasted condition.</description>
        <time_frame>Days 1 and 5 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>10 mg dose of RDEA3170, administered as 4 × 2.5 mg tablets, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From 0 to Infinity (AUC∞)</title>
          <description>AUC∞ of RDEA3170 the fasted condition.</description>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" lower_limit="105" upper_limit="164"/>
                    <measurement group_id="O2" value="130" lower_limit="95.9" upper_limit="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio (%)</param_type>
            <param_value>100</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.3</ci_lower_limit>
            <ci_upper_limit>115</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Terminal Half-life (t1/2)</title>
        <description>t1/2 of RDEA3170 following various treatments.</description>
        <time_frame>Days 1 and 5 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>10 mg dose of RDEA3170, administered as 4 × 2.5 mg tablets, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (low-fat, high calorie meal).</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (high-fat, high calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Half-life (t1/2)</title>
          <description>t1/2 of RDEA3170 following various treatments.</description>
          <units>hr</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="11.6" upper_limit="23.4"/>
                    <measurement group_id="O2" value="15.5" lower_limit="10.6" upper_limit="22.5"/>
                    <measurement group_id="O3" value="15.4" lower_limit="11.6" upper_limit="20.4"/>
                    <measurement group_id="O4" value="16.6" lower_limit="11.5" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Effect of High Fat Meal on the PK of RDEA3170 Tablets</title>
        <description>Cmax of RDEA3170 in high-fat fed state.</description>
        <time_frame>Days 1 to 13 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment D</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (high-fat, high calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Effect of High Fat Meal on the PK of RDEA3170 Tablets</title>
          <description>Cmax of RDEA3170 in high-fat fed state.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="11.9" upper_limit="18.8"/>
                    <measurement group_id="O2" value="27.2" lower_limit="20.2" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio (%)</param_type>
            <param_value>182</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>144</ci_lower_limit>
            <ci_upper_limit>230</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC Last: Effect of High Fat Meal on the PK of RDEA3170 Tablets</title>
        <description>AUC last of RDEA3170 in high-fat fed state.</description>
        <time_frame>Days 1 to 13 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment D</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (high-fat, high calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Last: Effect of High Fat Meal on the PK of RDEA3170 Tablets</title>
          <description>AUC last of RDEA3170 in high-fat fed state.</description>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="85.7" upper_limit="153"/>
                    <measurement group_id="O2" value="160" lower_limit="130" upper_limit="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio (%)</param_type>
            <param_value>140</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>121</ci_lower_limit>
            <ci_upper_limit>163</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞: Effect of High Fat Meal on the PK of RDEA3170 Tablets</title>
        <description>AUC∞ of RDEA3170 in high-fat fed state.</description>
        <time_frame>Days 1 to 13 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment D</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (high-fat, high calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Effect of High Fat Meal on the PK of RDEA3170 Tablets</title>
          <description>AUC∞ of RDEA3170 in high-fat fed state.</description>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" lower_limit="95.9" upper_limit="176"/>
                    <measurement group_id="O2" value="173" lower_limit="137" upper_limit="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio (%)</param_type>
            <param_value>134</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>114</ci_lower_limit>
            <ci_upper_limit>156</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Effect of Low Fat Meal on the PK of RDEA3170 Tablets</title>
        <description>Cmax of RDEA3170 in low-fat fed state.</description>
        <time_frame>Days 1 to 9 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (low-fat, high calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Effect of Low Fat Meal on the PK of RDEA3170 Tablets</title>
          <description>Cmax of RDEA3170 in low-fat fed state.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="11.9" upper_limit="18.8"/>
                    <measurement group_id="O2" value="11.8" lower_limit="9.23" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio (%)</param_type>
            <param_value>79.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>66.4</ci_lower_limit>
            <ci_upper_limit>94.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC Last: Effect of Low Fat Meal on the PK of RDEA3170 Tablets</title>
        <description>AUC last of RDEA3170 in low-fat fed state.</description>
        <time_frame>Days 1 to 9 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (low-fat, high calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Last: Effect of Low Fat Meal on the PK of RDEA3170 Tablets</title>
          <description>AUC last of RDEA3170 in low-fat fed state.</description>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="85.7" upper_limit="153"/>
                    <measurement group_id="O2" value="97.8" lower_limit="77.3" upper_limit="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio (%)</param_type>
            <param_value>85.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.9</ci_lower_limit>
            <ci_upper_limit>98.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC∞: Effect of Low Fat Meal on the PK of RDEA3170 Tablets</title>
        <description>AUC∞ of RDEA3170 in low-fat fed state.</description>
        <time_frame>Days 1 to 9 at predose, 30 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment C</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (low-fat, high calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Effect of Low Fat Meal on the PK of RDEA3170 Tablets</title>
          <description>AUC∞ of RDEA3170 in low-fat fed state.</description>
          <units>ng·hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" lower_limit="95.9" upper_limit="176"/>
                    <measurement group_id="O2" value="108" lower_limit="84.4" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The sample size is not based on formal power calculations, as this study is designed only to provide an initial assessment of the PK, PD, and safety profile of RDEA3170.</non_inferiority_desc>
            <param_type>Geometric Least Squares mean Ratio (%)</param_type>
            <param_value>83.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.5</ci_lower_limit>
            <ci_upper_limit>94.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Dose Pharmacodynamics (PD) Profile of RDEA3170 From Serum and Urine</title>
        <description>PD profiles of uric acid from serum and urine. PD parameters were evaluated to assess whether any potential differences in PK for the 2 different tablets resulted in differences in uric acid excretion.</description>
        <time_frame>Day -1: -24, -23, -22, -21, -20, -18, -16, -14, and -12 hours predose. Days 1, 5, 9, and 13: predose (within 30 minutes prior to dosing) and 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>10 mg dose of RDEA3170, administered as 4 × 2.5 mg tablets, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (low-fat, high calorie meal).</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (high-fat, high calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>Single Dose Pharmacodynamics (PD) Profile of RDEA3170 From Serum and Urine</title>
          <description>PD profiles of uric acid from serum and urine. PD parameters were evaluated to assess whether any potential differences in PK for the 2 different tablets resulted in differences in uric acid excretion.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Urate Maximum % Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.4" spread="2.08"/>
                    <measurement group_id="O2" value="-34.4" spread="2.27"/>
                    <measurement group_id="O3" value="-37.3" spread="1.89"/>
                    <measurement group_id="O4" value="-49.0" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Uric Acid % Change(0-24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" spread="12.5"/>
                    <measurement group_id="O2" value="78.5" spread="8.38"/>
                    <measurement group_id="O3" value="53.4" spread="8.85"/>
                    <measurement group_id="O4" value="65.9" spread="9.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal Clearance of Uric Acid % Change (0-24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170" spread="19.5"/>
                    <measurement group_id="O2" value="147" spread="15.6"/>
                    <measurement group_id="O3" value="128" spread="18.9"/>
                    <measurement group_id="O4" value="179" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fractional Excretion of Uric Acid % Change (0-24h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" spread="15.1"/>
                    <measurement group_id="O2" value="151" spread="22.0"/>
                    <measurement group_id="O3" value="149" spread="22.7"/>
                    <measurement group_id="O4" value="199" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Treatment-Emergent Adverse Events</title>
        <time_frame>7 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>10 mg dose of RDEA3170, administered as 4 × 2.5 mg tablets, in the fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (low-fat, high calorie meal).</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (high-fat, high calorie meal).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-Emergent Adverse Events</title>
          <units>Number of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks</time_frame>
      <desc>Overall number of baseline participants used to determine number of participants at risk.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>10 mg dose of RDEA3170, administered as 4 × 2.5 mg tablets, in the fasted state.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fasted state.</description>
        </group>
        <group group_id="E3">
          <title>Treatment C</title>
          <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (low-fat, high calorie meal).</description>
        </group>
        <group group_id="E4">
          <title>Treatment D</title>
          <description>10 mg dose of RDEA3170, administered as a single 10 mg tablet, in the fed state (high-fat, high calorie meal).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall submit a copy of the Publication to Sponsor for review at least 45 days prior to its proposed submission. Sponsor reserves the right to delay any such publication for an additional period of 60 days. Upon Sponsor's request, PI agrees to delete from the proposed publication any Confidential Information. PI agrees not to release any publication without the prior written permission of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jesse Hall, MD</name_or_title>
      <organization>Study Information Center AstraZeneca</organization>
      <phone>+1 877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

